The Effect of Different Doses of Intracameral Bevacizumab on Surgical Outcomes of Trabeculectomy for Neovascular Glaucoma

Abstract

The efficacy of an intracameral dose of 2.5 mg of bevacizumab prior to trabeculectomy for eyes with NVG is not significantly different from a 1.25 mg dose. Intracameral bevacizumab followed by trabeculectomy results in good surgical outcomes. Longer follow-up would be needed to evaluate differences in recurrence rates of iris neovascularization using different dosages.

Short-term Results of Trabeculectomy Using Adjunctive Intracameral Bevacizumab

“…Different doses of bevacizumab have been studied in various studies ranging from low dose of 0.2 mg to higher doses of 1.25 or 2.5 mg. One study has shown that 1.25 and 2.50 mg doses of intracameral bevacizumab are almost equally effective when used in neovascular glaucoma patients undergoing MMC-augmented trabeculectomy though. 43 Our study has some limitations which should be kept in mind. The follow-up period is short, so we cannot make any comments about long-term results of intracameral bevacizumab in our patients.…”

Adjunctive Intravitreal Bevacizumab-Combined Trabeculectomy Versus Trabeculectomy Alone in the Treatment of Neovascular Glaucoma

“…[5][6][7][19][20][21] Recent larger cases series and prospective design reports have revealed its effi cacy and safety. 13,[22][23][24][25] Ehlers and associates revealed that ivBe/PRP treatment resulted in more rapid decrease in IOP and regression of neovascularization than PRP alone in NVG. 13 Wakabayashi and associates showed from 41 consecutive cases of NVG secondary to ischemic retinal disease that ivBe was well-tolerated, effectively stabilized NVI, controlled IOP in patients with NVI alone and early-stage NVG, and improved surgical results when used adjunctively.…”

Changing paradigms of anti-VEGF in the Indian scenario

“…[123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869] The years between 2007-10, being populated largely by case reports and occasional case series detailing the use of anti-VEGF agents in treating CNVM of other etiology, and retinopathy of prematurity[41] (2007), AMD[3] and adjunct to trabeculectomy[44] (2008). We can see a trend towards randomized case-control studies comparing different anti-VEGF agents, the use of combination treatments in AMD and other diseases since 2011 onwards.…”